Look­ing for an edge in a com­pet­i­tive mar­ket, Ox­ford Nanopore moves in­to mR­NA vac­cine test­ing

Re­searchers at the Uni­ver­si­ty of Queens­land say they’ve de­vel­oped a faster way to put mR­NA vac­cines through qual­i­ty con­trol test­ing, ac­cord­ing to a study pub­lished to­day in Na­ture Com­mu­ni­ca­tions.

Ox­ford Nanopore, the com­pa­ny whose tech­nol­o­gy is in­te­gral to the process, is tout­ing the find­ings as it looks for an edge in the in­creas­ing­ly com­pet­i­tive space of ge­net­ic se­quenc­ing. Com­pa­nies like Ox­ford Nanopore and Il­lu­mi­na read DNA for re­search and di­ag­nos­tic pur­pos­es, but Ox­ford Nanopore sees big po­ten­tial in test­ing mR­NA vac­cines and ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.